Rare cancers and blood diseases present unique diagnostic and treatment challenges, often requiring specialized expertise and multidisciplinary care. In this episode of Cancer Advances, Sudipto Mukherjee, MD, PhD, MPH, discusses how Cleveland Clinic's Rare Cancers and Blood Diseases Program is improving diagnostic accuracy, accelerating access to care and advancing research across more than 90 rare conditions. Learn how integrated pathology review, genomic insights, collaborative care models and emerging therapeutic targets are helping improve outcomes for patients with rare diseases.

Hematologist and myeloma specialist Shahzad Raza, MD, joins the Cancer Advances podcast to discuss emerging cellular and immune therapies for AL amyloidosis. Listen as Dr. Raza reviews early data on CAR T-cell therapy and bispecific antibodies, their potential to induce deep hematologic responses and how these approaches may improve organ function and long-term outcomes for patients with this rare plasma cell disorder.

As recommendations for germline genetic testing continue to expand, many eligible patients remain untested. In this episode of Cancer Advances, Demitrios Dedousis, MD, discusses current testing indications, common gaps in implementation and the clinical implications of identifying hereditary cancer predisposition syndromes. Learn how germline findings can influence treatment decisions, screening protocols and risk assessment for families.